This abstract presents how RGI can be used in drug development for pharmacodynamic and pharmacokinetic assessment of cellular, gene, oncolytic viral and immunotherapeutic approaches using MRI, PET, SPECT, Ultrasound, Bioluminescence and Fluoroscence. Some of the teaching points include further insight into RGI imaging probes that can be direct, indirect or activable; range from enzymes, protein receptors and cell membrane transporters and how RGI qualitatively and quantitatively assesses cell targeting, transfection, protein expression and intracellular processes.
Reporter Gene Imaging and its Role in Imaging-Based Drug Development.
July 1, 2019
Radiology Society of North America 2019
F Shaikh, MD; E Kurtys, PhD; O A Kubassova, PhD; D Roettger, PhD; T Haywood